The U.S. Army has just published the 2013 edition of its annual Weapon Systems Handbook, which is filled with updated information on dozens of weapon systems, the military contractors who produce them, and the foreign countries that purchase them.
So one learns, for example, that the RQ-11B Raven Small Unmanned Aircraft System is marketed to Denmark, Estonia, Lebanon, and Uganda, while the United States sells artillery ammunition both to Israel and to Lebanon.
An appendix provides an informative breakdown of military industry contractors by weapon system and by the state where the contractor is located.
“The systems listed in this book are not isolated, individual products. Rather, they are part of an integrated Army system of systems designed to equip the Army of the future to successfully face any challenges,” according to the Handbook introduction.
“After 10 years of combat, today’s Army is significantly more capable than the Army of 2001. As we draw down from Iraq and Afghanistan, we must remain flexible, adaptable, and agile enough to respond and meet the needs of the combatant commanders.”
“Our objective is to equip and maintain an Army with the latest most advanced weaponry to win and return home quickly.”
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
As the efficacy of environmental laws has waned, so has their durability. What was once a broadly shared goal – protecting Americans from environmental harm – is now a political football, with rules that whipsaw back and forth depending on who’s in charge.